Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D08JAC
|
||||
Former ID |
DIB003719
|
||||
Drug Name |
Fenretinide
|
||||
Synonyms |
RT-101; ST-602; SYT-101; Fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University; LXS/4-HPR; Fenretinide (Ewing's sarcoma), Cancer Research UK; Fenretinide (ILE formulation), Children's Hospital LA; Fenretinide (intralipid emulsion formulation), Children's Hospital of Los Angeles; Fenretinide (intravenous, cancer), SciTech Development; Fenretinide (iv), Children's Hospital LA; Fenretinide (oral, AMD), Sytera; Fenretinide (soft gel capsule, AMD), ReVision Therapeutics; Fenretinide (soft gel capsule, AMD), Sirion; Fenretinide (topical, actinic keratosis and cancer), SciTech Development; N-(4-hydroxyphenyl)retinamide; Fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx; Fenretinide (oral powder/Lym-X-Sorb, neuroblastoma), BioMolecular Products; 4-HPR
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Macular degeneration [ICD9: 362.5; ICD10:H35.3] | Phase 3 | [521449] | ||
Company |
Sirion Therapeutics; cerrx; Sytera Inc
|
||||
Structure |
Download2D MOL |
||||
Formula |
C26H33NO2
|
||||
Canonical SMILES |
C1(=C(CCCC1(C)C)C)/C=C/C(=C/C=C/C(=C/C(=O)Nc1ccc(cc1)O)<br />/C)/C
|
||||
CAS Number |
CAS 65646-68-6
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Retinoic acid receptor | Target Info | Modulator | [550397] | |
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.